While most startups are chasing the AI wave, one biotech company is setting its sights on a different kind of longevity—extending the lives of cats. The Cat Health Company announced today that it has raised $1.2 million in fresh financing to push forward its work in feline therapeutics, aiming to help cats live longer and healthier lives.
The round brought in new investors, including Portfolia’s Active Aging & Longevity Fund II, Sonia Arrison’s 100 Plus Capital, and Alex Zhavoronkov, the founder of Insilico Medicine. A syndicated angel SPV also participated, while early backer Early Game Ventures doubled down with follow-on capital.
What drew investors in was encouraging early clinical data that validated the company’s approach and strengthened its pipeline. Those results have caught the attention of key players in longevity research, who chose to lead this SAFE round.
“This is more than just an investment; it’s a vote of confidence in our mission to bring true longevity solutions for the veterinary world,” said Alex Voda, CEO of The Cat Health Company. COO Alex Bacita added: “With this funding, we will accelerate our clinical research, develop new programs, and also expand our team to make sure we can bring these life-extending therapies to the cats who need them most, faster.”
The young biotech startup plans to publish a new set of clinical data and submit it to regulators in early 2026. Its focus is clear: to combat age-related diseases in cats and improve the overall quality of life for companion animals.
Founded to address a blind spot in longevity medicine—pets often get left out of the conversation—The Cat Health Company has positioned itself as the leading biotech in feline longevity. And with today’s funding, it’s betting that science can give cats not just more years, but better ones.